Brian A Keller, Gareth Palidwor, Elena Pastukhova, Zuzanna Gorski, Nicola Schieda, Kevin Hogan, Paul Borowy-Borowski, Harman Sekhon, Trevor A Flood
{"title":"阴茎鳞状细胞癌的RNA-seq显示ODC1过表达与较差的总生存率相关。","authors":"Brian A Keller, Gareth Palidwor, Elena Pastukhova, Zuzanna Gorski, Nicola Schieda, Kevin Hogan, Paul Borowy-Borowski, Harman Sekhon, Trevor A Flood","doi":"10.1007/s00428-025-04166-7","DOIUrl":null,"url":null,"abstract":"<p><p>Penile squamous cell carcinoma (PSCC) is classified into human papillomavirus (HPV)-associated and HPV-independent subtypes. Aggressive and metastatic PSCCs pose significant treatment challenges due to limited effective systemic options. Polyamines are essential intracellular regulators involved in cell proliferation and tumor progression, with ODC1 serving as the rate-limiting enzyme in polyamine metabolism. We used RNA sequencing on 21 PSCC tumors to investigate ODC1 expression. ODC1 overexpression was identified in 10/21 (47.6%) tumors with a higher prevalence in HPV-independent cases (7/12, 58.3%) compared to HPV-associated tumors (3/9, 33.3%). Immunohistochemistry confirmed ODC1 positivity in 5/21 (23.8%) tumors, all of which overexpressed ODC1 and were HPV-independent. Importantly, ODC1 overexpression and positive immunostaining correlated with significantly worse overall survival (p < 0.05). These results indicate that ODC1 overexpression and positive immunostaining are associated with poor prognosis in PSCC, supporting ODC1's value as a prognostic biomarker and highlighting its potential as a novel therapeutic target, given available anti-cancer drugs targeting ODC1 activity.</p>","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"RNA-seq of penile squamous cell carcinoma shows ODC1 overexpression is associated with worse overall survival.\",\"authors\":\"Brian A Keller, Gareth Palidwor, Elena Pastukhova, Zuzanna Gorski, Nicola Schieda, Kevin Hogan, Paul Borowy-Borowski, Harman Sekhon, Trevor A Flood\",\"doi\":\"10.1007/s00428-025-04166-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Penile squamous cell carcinoma (PSCC) is classified into human papillomavirus (HPV)-associated and HPV-independent subtypes. Aggressive and metastatic PSCCs pose significant treatment challenges due to limited effective systemic options. Polyamines are essential intracellular regulators involved in cell proliferation and tumor progression, with ODC1 serving as the rate-limiting enzyme in polyamine metabolism. We used RNA sequencing on 21 PSCC tumors to investigate ODC1 expression. ODC1 overexpression was identified in 10/21 (47.6%) tumors with a higher prevalence in HPV-independent cases (7/12, 58.3%) compared to HPV-associated tumors (3/9, 33.3%). Immunohistochemistry confirmed ODC1 positivity in 5/21 (23.8%) tumors, all of which overexpressed ODC1 and were HPV-independent. Importantly, ODC1 overexpression and positive immunostaining correlated with significantly worse overall survival (p < 0.05). These results indicate that ODC1 overexpression and positive immunostaining are associated with poor prognosis in PSCC, supporting ODC1's value as a prognostic biomarker and highlighting its potential as a novel therapeutic target, given available anti-cancer drugs targeting ODC1 activity.</p>\",\"PeriodicalId\":23514,\"journal\":{\"name\":\"Virchows Archiv\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-07-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Virchows Archiv\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00428-025-04166-7\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virchows Archiv","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00428-025-04166-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
RNA-seq of penile squamous cell carcinoma shows ODC1 overexpression is associated with worse overall survival.
Penile squamous cell carcinoma (PSCC) is classified into human papillomavirus (HPV)-associated and HPV-independent subtypes. Aggressive and metastatic PSCCs pose significant treatment challenges due to limited effective systemic options. Polyamines are essential intracellular regulators involved in cell proliferation and tumor progression, with ODC1 serving as the rate-limiting enzyme in polyamine metabolism. We used RNA sequencing on 21 PSCC tumors to investigate ODC1 expression. ODC1 overexpression was identified in 10/21 (47.6%) tumors with a higher prevalence in HPV-independent cases (7/12, 58.3%) compared to HPV-associated tumors (3/9, 33.3%). Immunohistochemistry confirmed ODC1 positivity in 5/21 (23.8%) tumors, all of which overexpressed ODC1 and were HPV-independent. Importantly, ODC1 overexpression and positive immunostaining correlated with significantly worse overall survival (p < 0.05). These results indicate that ODC1 overexpression and positive immunostaining are associated with poor prognosis in PSCC, supporting ODC1's value as a prognostic biomarker and highlighting its potential as a novel therapeutic target, given available anti-cancer drugs targeting ODC1 activity.
期刊介绍:
Manuscripts of original studies reinforcing the evidence base of modern diagnostic pathology, using immunocytochemical, molecular and ultrastructural techniques, will be welcomed. In addition, papers on critical evaluation of diagnostic criteria but also broadsheets and guidelines with a solid evidence base will be considered. Consideration will also be given to reports of work in other fields relevant to the understanding of human pathology as well as manuscripts on the application of new methods and techniques in pathology. Submission of purely experimental articles is discouraged but manuscripts on experimental work applicable to diagnostic pathology are welcomed. Biomarker studies are welcomed but need to abide by strict rules (e.g. REMARK) of adequate sample size and relevant marker choice. Single marker studies on limited patient series without validated application will as a rule not be considered. Case reports will only be considered when they provide substantial new information with an impact on understanding disease or diagnostic practice.